Academic Journal
Folate-Targeted PEGylated Magnetoliposomes for Hyperthermia-Mediated Controlled Release of Doxorubicin
| العنوان: | Folate-Targeted PEGylated Magnetoliposomes for Hyperthermia-Mediated Controlled Release of Doxorubicin |
|---|---|
| المؤلفون: | Cintra, Emílio R., Hayasaki, Tacio G., Sousa-Junior, Ailton A., Silva, Artur C. G., Valadares, Marize C., Bakuzis, Andris F., Mendanha, Sebastião A., Lima, Eliana M. |
| المصدر: | Frontiers in Pharmacology ; volume 13 ; ISSN 1663-9812 |
| بيانات النشر: | Frontiers Media SA |
| سنة النشر: | 2022 |
| المجموعة: | Frontiers (Publisher - via CrossRef) |
| الوصف: | Doxorubicin (DOX) is a chemotherapeutic agent commonly used for the treatment of solid tumors. However, the cardiotoxicity associated with its prolonged use prevents further adherence and therapeutic efficacy. By encapsulating DOX within a PEGylated liposome, Doxil ® considerably decreased DOX cardiotoxicity. By using thermally sensitive lysolipids in its bilayer composition, ThermoDox ® implemented a heat-induced controlled release of DOX. However, both ThermoDox ® and Doxil ® rely on their passive retention in tumors, depending on their half-lives in blood. Moreover, ThermoDox ® ordinarily depend on invasive radiofrequency-generating metallic probes for local heating. In this study, we prepare, characterize, and evaluate the antitumoral capabilities of DOX-loaded folate-targeted PEGylated magnetoliposomes (DFPML). Unlike ThermoDox ® , DOX delivery via DFPML is mediated by the heat released through dynamic hysteresis losses from magnetothermal converting systems composed by MnFe 2 O 4 nanoparticles (NPs) under AC magnetic field excitation—a non-invasive technique designated magnetic hyperthermia (MHT). Moreover, DFPML dismisses the use of thermally sensitive lysolipids, allowing the use of simpler and cheaper alternative lipids. MnFe 2 O 4 NPs and DFPML are fully characterized in terms of their size, morphology, polydispersion, magnetic, and magnetothermal properties. About 50% of the DOX load is released from DFPML after 30 min under MHT conditions. Being folate-targeted, in vitro DFPML antitumoral activity is higher (IC 50 ≈ 1 μg/ml) for folate receptor-overexpressing B16F10 murine melanoma cells, compared to MCF7 human breast adenocarcinoma cells (IC 50 ≈ 4 μg/ml). Taken together, our results indicate that DFPML are strong candidates for folate-targeted anticancer therapies based on DOX controlled release. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| DOI: | 10.3389/fphar.2022.854430 |
| DOI: | 10.3389/fphar.2022.854430/full |
| الاتاحة: | http://dx.doi.org/10.3389/fphar.2022.854430 https://www.frontiersin.org/articles/10.3389/fphar.2022.854430/full |
| Rights: | https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.4CE0BAAB |
| قاعدة البيانات: | BASE |
| DOI: | 10.3389/fphar.2022.854430 |
|---|